drugset / Trial / NCT02903160
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the clinical benefits of using a rapidly cycling, non-cross reactive regimen of FDA-approved prostate cancer therapeutic agents in the management of castration resistant prostate cancer. The hypothesis is that the identification of optimal combinations and sequencing of therapies can help prevent or delay the development of therapeutic drug resistance, and can be safely tolerated.
Timeline
- Start
- 2017-01-13
- Primary completion
- 2021-11-15
- Completion
- 2021-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Cabazitaxel | Other / unclassified | 25 mg/m2 | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Radium-223 dichloride | Other / unclassified | 0.05 mbq/kg | Intravenous |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |